CRISPR News and Research

Latest CRISPR News and Research

CRISPR-Cas13 emerges as a game changer in RNA-targeted therapies

In recent years, the scientific community has made significant strides in the field of gene editing, particularly through the development of the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) systems.

25 Sep 2024

Researchers gain new understanding of how immune cells respond to heat during fever

The study reveals that moderate fever enhances CD4 T cell activity while reducing regulatory T cell suppression, highlighting temperature's immune effects.

25 Sep 2024

New CRISPR model offers deeper insight into prostate cancer metastasis

A new preclinical model using CRISPR, an advanced technology that allows scientists to cut and edit genes, has given Weill Cornell Medicine researchers and their colleagues a deeper insight into how prostate cancer spreads or metastasizes.

23 Sep 2024

The role of CRISPR-Cas9 in combating mosquito-borne diseases

Announcing a new article publication for Zoonoses journal. As global warming increases, mosquito activity areas are expanding, alongside changes in the natural environment and the misuse of insecticides, thus further increasing mosquito resistance and exposing the world to an elevated risk of mosquito-borne diseases.

23 Sep 2024

Enhanced TnpB protein offers new possibilities for gene editing

CRISPR-Cas is used broadly in research and medicine to edit, insert, delete or regulate genes in organisms. TnpB is an ancestor of this well-known "gene scissor" but is much smaller and thus easier to transport into cells.

23 Sep 2024

MaxCyte signs strategic platform license with Kamau Therapeutics to accelerate the development of cell therapies for genetic diseases

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, and Kamau Therapeutics, a clinical-stage stem cell therapy gene correction company, today announced they are entering into a strategic platform license (SPL) agreement.

From MaxCyte, Inc. 23 Sep 2024

Research shows brain synchronization between humans and dogs

Study shows interbrain synchronization in humans and dogs during social interactions, highlighting the impact of autism-related gene mutations in dogs.

16 Sep 2024

New discovery offers hope for overcoming CAR-T cell therapy resistance

Mayo Clinic researchers mined the molecular foundations of cancer and uncovered a new reason chimeric antigen receptor (CAR-T cell therapy) fails in some patients.

12 Sep 2024

Researchers uncover why typically normal protein drives prostate cancer

NSD-2 is crucial for AR activity in prostate cancer, promoting tumor growth and offering a potential therapeutic target for advanced prostate cancer treatment.

12 Sep 2024

VitelloTag approach offers new solution for gene editing challenges in egg cells

A new approach for delivering miniature research tools into the interior of egg cells and embryos has been developed at the Marine Biological Laboratory (MBL), resolving a major bottleneck to using the gene-editing tool CRISPR-Cas9 in many research organisms.

11 Sep 2024

A promising new therapeutic target for MASLD identified

Using a novel stem cell platform, a team of the Medical University of South Carolina researchers has identified a pathway that could be targeted by drugs to reduce fat accumulation in patients with a common form of fatty liver disease known as metabolic dysfunction-associated steatotic liver disease, or MASLD.

11 Sep 2024

Researchers uncover mechanism fueling prostate cancer

Researchers at the University of Michigan Health Rogel Cancer Center have uncovered a key reason why a typically normal protein goes awry and fuels cancer.

9 Sep 2024

Gene therapy shows dramatic vision improvement for rare inherited condition

The vision of people with a rare inherited condition that causes them to lose much of their sight early in childhood was 100 times better after they received gene therapy to address the genetic mutation causing it.

5 Sep 2024

ERS Genomics and medicines discovery catapult sign CRISPR/Cas9 license agreement

Dublin, Ireland, and Cheshire, UK, 04 September 2024: ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and Medicines Discovery Catapult (‘MDC’), an independent, not-for-profit drug discovery innovation center, have signed a non-exclusive commercial-use CRISPR license agreement.

From ERS Genomics 5 Sep 2024

Scientists advance type 1 diabetes treatment with cutting-edge stem cell and gene editing technologies

Researchers review significant advancements and ongoing challenges in cell replacement therapies for type 1 diabetes, highlighting innovative approaches in stem cell-derived islets and immune protection strategies.

5 Sep 2024

Promising new strategy to combat fungal infections

A group of Brazilian researchers has found a potential target for novel therapeutic strategies to combat fungal infections – more specifically, those caused by Aspergillus fumigatus. An article reporting the discovery is published in the journal Communications Biology.

5 Sep 2024

CDK4/6 inhibitors show promise for pediatric high-grade glioma treatment

CDK4/6 inhibitors, which are already FDA approved for the treatment of other forms of cancer, show early signs of promise in the treatment of a subtype of pediatric high-grade glioma, according to new research from Dana-Farber Cancer Institute and the Institute of Cancer Research in London.

3 Sep 2024

Study reveals how bacteria pass on traits without DNA changes

Bacterial cells can "remember" brief, temporary changes to their bodies and immediate surroundings, a new Northwestern University and University of Texas-Southwestern study has found.

28 Aug 2024

16 promising postdoctoral scientists awarded Damon Runyon Fellowships for cancer research

The Damon Runyon Cancer Research Foundation has named 16 new Damon Runyon Fellows, exceptional postdoctoral scientists conducting basic and translational cancer research in the laboratories of leading senior investigators.

28 Aug 2024

Austocystin D's anticancer efficacy linked to CYP2J2 enzyme activity

Austocystin D, a natural compound produced by fungi, has been recognized for its cytotoxic effects and anticancer activity in various cell types. It exhibits potent activity even in cells that express proteins associated with multidrug resistance, attracting significant global research interest.

27 Aug 2024